Axsome Therapeutics
AXSM
226 hedge funds and large institutions have $2.65B invested in Axsome Therapeutics in 2023 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 87 increasing their positions, 71 reducing their positions, and 28 closing their positions.
53% more call options, than puts
Call options by funds: $56.4M | Put options by funds: $36.8M
25% more funds holding in top 10
Funds holding in top 10: 8 → 10 (+2)
23% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 71
2.14% more ownership
Funds ownership: 78.14% → 80.28% (+2.1%)
1% more capital invested
Capital invested by funds: $2.61B → $2.65B (+$33.4M)
7% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 28
2% less funds holding
Funds holding: 231 → 226 (-5)
Top Buyers
Top Sellers
AXSM Hedge Fund Activity: Q3 2023 in Review
226 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q3 2023, worth a combined $2.65B — up 1.3% from $2.61B a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of AXSM and 26 opened new positions — a net loss of 2 holders — while 71 trimmed existing stakes and 87 added.
The largest buyer was Citadel Advisors, adding an estimated $62.9M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $24.4M sold.
- 226 institutional investors held Axsome Therapeutics (AXSM) as of Q3 2023, down from 231 in Q2 2023.
- Funds reported $2.65B of Axsome Therapeutics stock for Q3 2023, up 1.3% quarter-over-quarter.
- 26 funds opened new Axsome Therapeutics positions in Q3 2023 and 28 closed out, a net change of -2 holders.
- The largest Axsome Therapeutics buyer in Q3 2023 was Citadel Advisors, an estimated $62.9M added.
- The largest Axsome Therapeutics seller in Q3 2023 was Cormorant Asset Management, an estimated $24.4M sold.
Based on aggregated 13F filings for Q3 2023.